

Epie Boven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2053920/publications.pdf>

Version: 2024-02-01

94
papers

4,257
citations

126708

33
h-index

118652

62
g-index

94
all docs

94
docs citations

94
times ranked

5772
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. <i>Cancers</i> , 2022, 14, 2838.	1.7	1
2	IGF1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 2348-2359.	2.3	18
3	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. <i>Molecular Oncology</i> , 2020, 14, 490-503.	2.1	14
4	PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3013-3023.	1.2	4
5	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. <i>Apmis</i> , 2020, 128, 298-307.	0.9	7
6	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2350-2356.	3.2	7
7	Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. <i>Pharmacological Research</i> , 2018, 128, 122-129.	3.1	15
8	Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. <i>British Journal of Cancer</i> , 2018, 119, 832-839.	2.9	15
9	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 1204-1212.	0.8	6
10	Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. <i>Frontiers in Pharmacology</i> , 2016, 7, 310.	1.6	14
11	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. <i>British Journal of Cancer</i> , 2016, 115, 940-948.	2.9	4
12	Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1335-1342.	2.9	34
13	Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1611-1620.	3.2	27
14	Secretome proteomics reveals candidate non-invasive biomarkers of <i>BRCA1</i> deficiency in breast cancer. <i>Oncotarget</i> , 2016, 7, 63537-63548.	0.8	14
15	Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1918-1927.	0.8	453
16	Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1481-1491.	1.2	35
17	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 68, 621-629.	0.9	75
18	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1477-1484.	0.8	19

#	ARTICLE	IF	CITATIONS
19	Adherence and patients'™ experiences with the use of oral anticancer agents. <i>Acta OncolÃ³gica</i> , 2014, 53, 259-267.	0.8	68
20	Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 1319-1334.	2.5	24
21	The use of capecitabine in daily practice: a study on adherence and patients' experiences. <i>Patient Preference and Adherence</i> , 2012, 6, 741.	0.8	10
22	Validation of Serum Amyloid Î± as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. <i>European Urology</i> , 2012, 62, 685-695.	0.9	21
23	Use and costs of oral anticancer agents in the Netherlands in the period 2000â€“2008. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1036-1044.	0.9	17
24	Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. <i>Human Brain Mapping</i> , 2012, 33, 2971-2983.	1.9	218
25	Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. <i>International Journal of Cancer</i> , 2012, 131, E484-93.	2.3	15
26	Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. <i>Human Brain Mapping</i> , 2011, 32, 1206-1219.	1.9	243
27	Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. <i>Anti-Cancer Drugs</i> , 2010, 21, 439-446.	0.7	58
28	Targeted therapies in renal cell cancer: recent developments in imaging. <i>Targeted Oncology</i> , 2010, 5, 95-112.	1.7	47
29	Perfusion CT and US of Colorectal Cancer Liver Metastases: A Correlative Study of Two Dynamic Imaging Modalities. <i>Ultrasound in Medicine and Biology</i> , 2010, 36, 1626-1636.	0.7	18
30	Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. <i>Acta OncolÃ³gica</i> , 2010, 49, 520-523.	0.8	45
31	Targeted therapy for renal cell cancer: current perspectives. <i>Discovery Medicine</i> , 2010, 10, 394-405.	0.5	28
32	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 4406-4412.	0.8	177
33	Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule. <i>Journal of Clinical Oncology</i> , 2009, 27, 1339-1340.	0.8	21
34	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. <i>Angiogenesis</i> , 2009, 12, 69-79.	3.7	58
35	Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. <i>World Journal of Urology</i> , 2009, 27, 533-539.	1.2	71
36	Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. <i>Anti-Cancer Drugs</i> , 2009, 20, 450-460.	0.7	27

#	ARTICLE	IF	CITATIONS
37	Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma. <i>International Journal of Clinical Oncology</i> , 2008, 13, 71-73.	1.0	2
38	Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. <i>Biochemical Pharmacology</i> , 2008, 75, 427-437.	2.0	32
39	Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. <i>Biochemical Pharmacology</i> , 2008, 76, 707-716.	2.0	22
40	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892.	3.2	127
41	Brain Metastases in Patients With Renal Cell Cancer Receiving New Targeted Treatment. <i>Journal of Clinical Oncology</i> , 2008, 26, 152-154.	0.8	42
42	Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response. <i>Clinical Cancer Research</i> , 2008, 14, 2431-2436.	3.2	163
43	Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts. <i>Anti-Cancer Drugs</i> , 2008, 19, 721-727.	0.7	30
44	6-Methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor-induced resistance against temozolomide in human melanoma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2807-2815.	1.9	11
45	The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis. <i>Melanoma Research</i> , 2007, 17, 155-168.	0.6	6
46	Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor 1 activity in human ovarian cancer cells. <i>Biochemical Pharmacology</i> , 2007, 74, 191-201.	2.0	61
47	VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. <i>Thrombosis and Haemostasis</i> , 2007, 98, 440-50.	1.8	9
48	Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2348-2357.	1.9	102
49	Pronounced Antitumor Efficacy by Extracellular Activation of a Doxorubicin-Glucuronide Prodrug After Adenoviral Vector-Mediated Expression of a Human Antibody-Enzyme Fusion Protein. <i>Human Gene Therapy</i> , 2004, 15, 229-238.	1.4	15
50	Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts. <i>Clinical Cancer Research</i> , 2004, 10, 1180-1191.	3.2	44
51	Lecithinized copper,zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice. <i>Toxicology and Applied Pharmacology</i> , 2004, 194, 180-188.	1.3	30
52	Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. <i>Biochemical Pharmacology</i> , 2004, 68, 493-502.	2.0	19
53	A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. <i>Biochemical Pharmacology</i> , 2004, 68, 2273-2281.	2.0	29
54	Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 525-529.	1.1	7

#	ARTICLE	IF	CITATIONS
55	Cytosolic β -glycosidases for activation of glycoside prodrugs of daunorubicin. <i>Biochemical Pharmacology</i> , 2003, 65, 1875-1881.	2.0	16
56	Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 157-169.	2.3	29
57	Evidence for a Role of p38 Kinase in Hypoxia-inducible Factor 1-independent Induction of Vascular Endothelial Growth Factor Expression by Sodium Arsenite. <i>Journal of Biological Chemistry</i> , 2003, 278, 6885-6895.	1.6	73
58	Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 765-71.	1.9	19
59	Vascular Endothelial Growth Factor-165 Overexpression Stimulates Angiogenesis and Induces Cyst Formation and Macrophage Infiltration in Human Ovarian Cancer Xenografts. <i>American Journal of Pathology</i> , 2002, 160, 537-548.	1.9	80
60	Beta-Glucuronidase-Mediated Drug Release. <i>Current Pharmaceutical Design</i> , 2002, 8, 1391-1403.	0.9	138
61	Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. <i>Biochemical Pharmacology</i> , 2002, 63, 733-743.	2.0	51
62	A doxorubicin- α -CNGRC-peptide conjugate with prodrug properties. <i>Biochemical Pharmacology</i> , 2002, 63, 897-908.	2.0	72
63	The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. <i>Biochemical Pharmacology</i> , 2002, 64, 1267-1277.	2.0	33
64	Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: Determination of efficacy and possible mechanisms of resistance. <i>International Journal of Cancer</i> , 2002, 100, 22-29.	2.3	39
65	Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 371-6.	1.9	145
66	American Association for Cancer Research - 93rd Annual Meeting. 6-10 April 2002, San Francisco, CA, USA. <i>IDrugs: the Investigational Drugs Journal</i> , 2002, 5, 403-7.	0.7	0
67	Induction of Vascular Endothelial Growth Factor Expression and Hypoxia-inducible Factor 1 β Protein by the Oxidative Stressor Arsenite. <i>Journal of Biological Chemistry</i> , 2001, 276, 48066-48076.	1.6	103
68	New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. <i>International Journal of Cancer</i> , 2000, 88, 260-266.	2.3	76
69	Development of a Panel of 15 Human Ovarian Cancer Xenografts for Drug Screening and Determination of the Role of the Glutathione Detoxification System. <i>Gynecologic Oncology</i> , 2000, 76, 362-368.	0.6	38
70	New Analogues of Camptothecins: Activity and Resistance. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 175-177.	1.8	18
71	Novel anthracycline-spacer- β -glucuronide, β -glucoside, and β -galactoside prodrugs for application in selective chemotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 1597-1610.	1.4	66
72	Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. <i>Biochemical Pharmacology</i> , 1999, 57, 673-680.	2.0	18

#	ARTICLE	IF	CITATIONS
73	Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human \hat{I}^2 -glucuronidase. <i>Cancer Immunology, Immunotherapy</i> , 1998, 45, 266-272.	2.0	16
74	[^{186}Re]-labeled mouse and chimeric monoclonal antibody 323/A3: A comparison of the efficacy in experimental human ovarian cancer. <i>Nuclear Medicine and Biology</i> , 1998, 25, 37-45.	0.3	4
75	Glutathione S-transferase activity and subunit composition in transitional cell cancer and mucosa of the human bladder. <i>Urology</i> , 1997, 49, 644-651.	0.5	28
76	Comparison of the biodistribution and the efficacy of monoclonal antibody labeled with either ^{131}I or ^{186}Re in human ovarian cancer xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 813-823.	0.4	18
77	Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer. <i>International Journal of Cancer</i> , 1997, 71, 237-245.	2.3	7
78	Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. , 1997, 73, 891-896.		29
79	Improved Characteristics of a Human \hat{I}^2 -Glucuronidase \hat{I}^2 Antibody Conjugate after Deglycosylation for Use in Antibody-Directed Enzyme Prodrug Therapy. <i>Bioconjugate Chemistry</i> , 1996, 7, 606-611.	1.8	21
80	Characterization of novel anthracycline prodrugs activated by human \hat{I}^2 -glucuronidase for use in antibody-directed enzyme prodrug therapy. <i>Biochemical Pharmacology</i> , 1996, 52, 455-463.	2.0	56
81	Synthesis and evaluation of novel daunomycin-phosphate-sulfate \hat{I}^2 -glucuronide and \hat{I}^2 -glucoside prodrugs for application in adept. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 2975-2980.	1.0	17
82	\hat{I}^2 -Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPT. <i>Tetrahedron Letters</i> , 1995, 36, 1701-1704.	0.7	26
83	Schedule dependence of sensitivity to $2\hat{I}^2,2\hat{I}^2$ -difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. <i>Biochemical Pharmacology</i> , 1994, 48, 1327-1339.	2.0	111
84	Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies directed against intracellular antigens. <i>Journal of Immunological Methods</i> , 1992, 154, 55-60.	0.6	2
85	Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 343-348.	2.0	32
86	Influence of dose and schedule on the therapeutic efficacy of ^{131}I -labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. <i>International Journal of Cancer</i> , 1992, 50, 474-480.	2.3	13
87	Comparison of ^{131}I -labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts. <i>International Journal of Cancer</i> , 1992, 51, 108-115.	2.3	11
88	Human ovarian cancer xenografts in nude mice: Characterization and analysis of antigen expression. <i>International Journal of Cancer</i> , 1991, 47, 72-79.	2.3	48
89	Tumour localisation with ^{131}I -labelled human IgM monoclonal antibody 16.88 in advanced colorectal cancer patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1430-1436.	0.9	14
90	The effects of \hat{I}^3 -interferon combined with 5-fluorouracil or 5-fluoro- $2\hat{I}^2$ -deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. <i>International Journal of Cancer</i> , 1991, 48, 749-756.	2.3	36

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice. <i>Cancer Immunology, Immunotherapy</i> , 1991, 34, 191-197.	2.0	5
92	Preclinical phase II studies in human tumor lines: A European multicenter study. <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 567-573.	0.9	34
93	Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 124-8.	1.1	12
94	Recovery from mitomycin C-induced hemolytic uremic syndrome: A case report. <i>Cancer</i> , 1984, 54, 2878-2881.	2.0	24